Key statistics dashboard for Contineum Therapeutics, Inc. (CTNM). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
Stock Data
| Price | $13.76 |
| Market Cap | $518M |
| Enterprise Value | $509.5M |
| Beta | 1.39 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -7.99 |
| Price / Book | 2.16 |
| P/S | 0.00 |
| EV/EBITDA | -7.72 |
| EV/Sales | 0.00 |
| EV/FCF | -9.53 |
| P/FCF | -9.72 |
| Earnings Yield | -11.16% |
| FCF Yield | -10.33% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -24.73% |
| Return on Assets | -22.99% |
| Return on Invested Capital | -26.96% |
| Return on Capital Employed | -27.22% |
Financial Health
| Current Ratio | 37.17 |
| Quick Ratio | 37.17 |
| Cash Ratio | 2.25 |
| Debt / Equity | 0.03 |
| Debt / Assets | 2.63% |
| Net Debt / EBITDA | 0.12 |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 2 |
| Altman Z-Score | 11.55 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 6.40 |
| Cash per share | 6.31 |
| FCF per share | -1.43 |
| Tangible Book Value per share | 6.40 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 2 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 3 |
| Avg rating (1-5) | 0.67 |
Related companies: ACIU · ALDX · AMRN · ANRO · CADL · CAPR · KYTX
Explore sector: Healthcare · Biotechnology
More sections of CTNM: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks